Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2003
Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tobias Joseph D, Berkenbosch John W, Russo Pierantonio
Аннотация
OBJECTIVE: The authors present the use of synthetic factor VIIa to treat bleeding after cardiopulmonary bypass and surgical repair of an atrial septal defect in an infant with trisomy 10 and pulmonary hypertension.
DESIGN: Case report.
SETTING: University-affiliated pediatric intensive care unit.
PATIENTS: A 4-mo-old, 3.7-kg infant.
MAIN RESULTS: After a single dose of synthetic factor VIIa, there was normalization of the prothrombin and partial thromboplastin time and cessation of bleeding.
CONCLUSION: The potential benefits of synthetic factor VIIa when compared with conventional therapy with fresh frozen plasma are discussed. Previous experience with synthetic factor VIIa in pediatric-aged patients and the cardiothoracic surgical population is presented.
DESIGN: Case report.
SETTING: University-affiliated pediatric intensive care unit.
PATIENTS: A 4-mo-old, 3.7-kg infant.
MAIN RESULTS: After a single dose of synthetic factor VIIa, there was normalization of the prothrombin and partial thromboplastin time and cessation of bleeding.
CONCLUSION: The potential benefits of synthetic factor VIIa when compared with conventional therapy with fresh frozen plasma are discussed. Previous experience with synthetic factor VIIa in pediatric-aged patients and the cardiothoracic surgical population is presented.